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Abstract
Background: Vascular homeostasis and response to injury are dependent on the coordinated activity of growth
factors such as vascular endothelial growth factor-A (VEGF). VEGF signaling is mediated by VEGF receptors 1
(VEGFR1) and 2 (VEGFR2). VEGF also binds to extracellular matrix (ECM) and neuropilin (NP), a cell surface
glycoprotein that enhances VEGF binding to VEGFR2 while inhibiting VEGF-VEGFR1 interactions. Proteases such as
neutrophil elastase release VEGF bound to ECM; however, this results in proteolytic processing of VEGF to a smaller
species termed VEGF fragment (VEGFf). We hypothesized that the generation and presence of VEGFf would have
significant effects on the binding distribution of VEGF.
Results: We show that VEGFf, unlike VEGF, does not bind ECM, fibronectin, or NP-1. Using computational
simulations, we find that excess VEGFf can lead to increased binding of VEGF to VEGFR2 through VEGFf binding to
VEGFR1 and subsequent liberation of NP-1. We show experimentally that VEGF-induced migration has a biphasic
response to conversion of VEGF to VEGFf. Simulations suggest that a simple change in VEGFR1 or VEGFR2
complexes are unlikely to be responsible and that a more complex integration of signals is more likely involved.
Conclusions: These findings suggest that proteolytic damage at sites of tissue injury and inflammation has the
potential to modulate the VEGF system through a complex process and highlight the need for quantitative analysis
to reveal mechanisms of growth factor control.
Background
Vascular endothelial growth factor-A (VEGF) plays criti-
cal roles in vasculogenesis, angiogenesis and in main-
taining vascular homeostasis [1,2]. VEGF functions as a
mitogenic, chemotactic, and survival factor for endothe-
lial cells, and has been shown to produce a pronounced
angiogenic response in a variety of in vivo and in vitro
models [1,2]. VEGF also induces vascular permeability
and vasodilatation, as well as activities associated with
non-vascular cell targets such as hematopoietic stem
cells, monocytes, osteoblasts and neurons. Consistent
with this wide range of important functions, deletion of
even one allele of the VEGF-A gene is embryonic lethal
showing impaired vasculogenesis and blood island for-
mation [3,4]. Targeted inactivation of the VEGF-A gene
in mouse lung causes an emphysematic phenotype sug-
gesting that VEGF also plays critical roles in alveolar
maintenance [5]. As a result of these critical activities,
considerable attention has been paid to VEGF as a ther-
apeutic agent and target for disease treatment. Focus
has primarily been on heparin-binding VEGF165.H o w -
ever, direct VEGF delivery or inactivation using blocking
antibodies produces mixed outcomes indicating that the
natural mechanisms of VEGF control are complex and
need to be better understood in order to design more
effective VEGF/anti-VEGF therapies [2].
VEGF activity is principally mediated by VEGF recep-
tors (VEGFR) 1 and 2 on vascular endothelial cells [1].
Interactions and signaling through these receptors are
also modulated by the co-receptors neuropilin (NP) 1
and 2 [6,7]. VEGFR2 (also known as KDR and Flk-1) is
a single pass transmembrane protein with high affinity
for VEGF that is believed to be the major signaling
receptor mediating the angiogenic activities of VEGF
[1]. The importance of VEGFR2 is revealed by a lack of
vasculogenesis and failure to develop blood islands and
organized blood vessels in VEGFR2-null mice resulting
in death in utero [8]. VEGFR1, on the other hand, has a
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sine kinase. Hence, VEGFR1 is often thought to act as
a ‘decoy’ receptor which functions by sequestering
VEGF from its signaling receptors, VEGFR2 [9]. How-
ever, the wide expression of VEGFR1 on non-endothe-
lial cells that do not express VEGFR2 suggests
functions for VEGFR1 that are independent of this
proposed ‘decoy’ role. NPs are cell surface glycopro-
teins that are proposed to function by presenting
VEGF165 to VEGFR2. There is no evidence that NPs
directly convey signals in response to VEGF binding,
but these co-receptors appear necessary for VEGF-
dependent angiogenesis [6] and some signal generation
[7]. Interestingly, NP-1 has been shown to form direct
complexes with VEGFR1 that result in decreased
VEGF binding to NP-1 and VEGFR1, but the function
of this interaction remains unclear [10]. Together these
studies suggest that the relative levels of available
VEGFRs and NPs on the cell surface may ultimately
dictate VEGF response. This system is likely also influ-
enced by the nature of the VEGF present, as some
VEGF isoforms are unable to bind to NP-1 or show
reduced affinity as does VEGF121[11].
VEGF is clearly an important regulatory protein sub-
ject to multiple levels of control. As noted above,
expression of VEGF receptors and co-receptors can
modulate function as can the expression of VEGF
itself. In addition, the ability of VEGF to bind to com-
ponents of the extracellular matrix, mainly heparan
sulfate and fibronectin, has been suggested to control
access of VEGF to cell surface receptors and provide a
means for establishing gradients of VEGF for directed
angiogenesis [12,13]. In this regard, we have recently
reported that neutrophil elastase (NE) releases VEGF
from the extracellular matrix (ECM) by processing it
to a smaller form that shows altered binding and activ-
ity [14]. In particular, the NE-generated VEGF frag-
ment (VEGFf) is unable to bind to VEGFR2 and shows
reduced binding to heparin. It is possible that inflam-
matory proteases modulate VEGF receptor binding
dynamics through the generation of VEGFf. Thus, in
the present study, we have characterized the relative
binding properties of VEGFf to NP-1, ECM and fibro-
nectin and incorporated this information into a model
of VEGF/VEGFf cell surface binding (Figure 1) to
reveal possible mechanisms for VEGF activity control.
These findings suggest that the generation of VEGFf
by NE at sites of inflammation may modulate VEGF-
mediated tissue repair by controlling cell surface bind-
ing events. This study highlights the complexity of the
VEGF-VEGFR system and reveals the importance of
applying system-wide analysis to identify non-intuitive
insight into the mechanisms controlling ligand-recep-
tor activation.
Methods
Materials
Human recombinant VEGF165, recombinant human Fc-
VEGFR2 chimera, Fc-VEGFR1 chimera and Fc-Neuropi-
lin 1 chimera were purchased from R&D systems (Min-
neapolis, MN).
125I-Bolton Hunter reagent was obtained
from PerkinElmer (Boston, MA). Heparin was from
Neoparin (San Leonardo, CA). Bovine serum albumin
(BSA) was obtained from American Bioanalytical
(Natick, MA). Purified human plasma fibronectin was
from Chemicon International( T e m e c u l a ,C A ) .D u l b e c -
co’s Modified Eagle’sm e d i a( D M E M ) ,p h o s p h a t eb u f -
fered saline (PBS) containing no Ca2+ and Mg2+,
penicillin/streptomycin, L-glutamine, N-(2-hydroxyethyl)
piperazine-N’-2-ethanesulfonic acid (HEPES) and tryp-
sin-EDTA were obtained from Invitrogen (Carlsbad,
CA). Calf serum (CS) was purchased from Hyclone
(Logan, UT). NE (human) was obtained from Elastin
Products (Owensville, MO).
Cell Culture
Bovine aortic endothelial cells (BAEC passage 5-15) were
maintained in low-glucose DMEM, supplemented with
10% CS, 5 mM L-glutamine, 100 U/ml penicillin G, and
100 (μg/ml streptomycin sulfate. Neonatal rat aortic
smooth muscle cells (SMCs) were isolated from Sprague-
Dawley rats, ages 1-3 days as described, and maintained
in low-glucose DMEM, with 10% FBS, 5 mM L-gluta-
mine, 100 U/ml penicillin G, and 100 (μg/ml streptomy-
cin sulfate and 1% nonessential amino acids.
VEGF Fragment (VEGFf) Generation
125I-labeled VEGF165, prepared using a modified Bolton-
Hunter procedure, was treated with varying NE concen-
trations in 44 mM sodium bicarbonate, pH 7.4, for var-
ious times at 37°C. Mock-treated
125I-VEGF was
Figure 1 Model illustrating VEGF and VEGFf binding
interactions. The following abbreviations are used: R1 for VEGFR1,
R2 for VEGFR2, NP-1 for neuropilin-1. Question mark indicates that it
is unknown if the binding reaction occurs.
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C. The reaction was stopped by adding 1 μM di-isopro-
pyl fluorophosphate (DFP). For large VEGFf prepara-
tions, the samples (NE and mock treated) were dialyzed
(10-kDa molecular weight cut off, Slide-A-Lyzer; Pierce,
Rockford, IL) against PBS at 4°C to remove DFP. The
concentration of
125I-VEGF165 and
125I-VEGFf in the
samples was determined by trichloracetic acid
precipitation.
VEGF/VEGFf Binding to VEGFR1 and Neuropillin 1/Fc
chimera
Binding assays were performed with VEGF binding chi-
meras by incubating a range of
125I-VEGF and
125I-
VEGFf concentrations with Fc-VEGFR1, Fc-NP-1, or
both in binding buffer (25 mM HEPES, pH 7.5, 150 mM
NaCl, and 1 mg/ml BSA) for 2 h at 4°C. The bound
complexes were pulled down with magnetic protein-A
beads (New England Biolabs, Beverly, MA). The beads
were washed three times with binding buffer, and
125I-
VEGF/
125I-VEGFf associated with the beads was mea-
sured using a Cobra Auto-Gamma 5005 counter (Pack-
ard Instruments, Meridian,CT).
VEGF/VEGFf Binding to Fibronectin
Fibronectin (10 μg/ml) in the presence of heparin (10 μg/
ml) was adsorbed overnight onto 96-well hydrophobic
polystyrene plates in PBS at 4°C (100 μl/well). Following
protein adsorption, the surface was washed three times
with PBS and once with binding buffer. VEGF/VEGFf bind-
ing assays were then conducted with various concentra-
tions of
125I-VEGF and
125I-VEGFf in 0.15 M NaCl, 25
mM HEPES, 1 mg/ml BSA, pH 7.5 for 2.5 h at 4°C (50 μl/
well). In some cases, plates were treated with various NE
concentrations for 30 min at 37°C, the NE solution
removed and plates washed three times with PBS then
incubated for 10 min with PBS containing 1 μMD F Pt o
inhibit any residual NE. VEGF binding to treated plates
was then measured by incubating the wells with the indi-
cated concentration of
125I-VEGF/VEGFf. Unbound VEGF/
VEGFf was removed by washing three times with binding
buffer and bound VEGF/VEGFf was extracted by 1 h incu-
bation with 5M NaCl, 25 mM HEPES, pH 7.5. The incuba-
tion was performed at room temperature with 50 μlo f
extraction solution per well. After each incubation period
the wells were washed once more with the same extraction
solution (50 μl/well) to ensure complete recovery of the
respective fraction of bound VEGF/VEGFf. The radioactiv-
ity released was measured by a Cobra Auto-Gamma 5005
counter (Packard Instruments, Meridian, CT).
VEGF Binding to Cell Culture Extracellular Matrices
Primary rat aortic smooth muscle cells and pulmonary
fibroblasts were plated onto 24-well plates (2 cm
2/well)
at an initial density of 5 × 10
4 per well. When the cells
reached confluence, the culture media was changed to
1% serum. Five days past-confluence
125I-VEGF/VEGFf
binding was conducted with isolated ECM. Isolated
ECM was used to evaluate the effects of elastase on
VEGF binding in order to avoid interference caused by
the effects of high elastase concentrations on the living
cells. To prepare cell-free ECM the cell layer was dis-
solved with 0.5% Triton, 20 mM NH4OH in PBS at 23°
C for 3 min, followed by three washes with PBS. The
isolated ECM was incubated with various concentrations
of NE for 30 min at 37°C, the elastase was inactivated
with 1 μM DFP and the ECM plates washed with PBS.
Isolated ECM were incubated with
125I-VEGF or
125I-
VEGFf in binding buffer (0.15 M NaCl, 25 mM HEPES,
pH 7.5, 1 mg/ml BSA) at 4°C for 2 h. Unbound ligand
was removed by washing the ECM layers three times
with binding buffer and VEGF/VEGFf bound to ECM
sites was extracted with 2 M NaCl, 25 mM HEPES, pH
7.5 and samples were counted in a gamma counter.
Cell Migration Assay
Migration assays were performed using a modified Boy-
den chamber technique using 24-well Transwell
®
permeable supports (Corning, NY) with migration
inserts (5 μmp o r es i z e ,6 . 5m md i a m e t e r ) .S e r u m
starved BAEC were plated onto the transwell inserts at
a density of 100,000 cells/insert in serum-free medium,
25 mM HEPES, pH 7.5 and 0.05% gelatin (v/v) and
placed in 24-well plates containing binding buffer +/-
chemoattractant (VEGF, VEGFf) at 0.45 nM. The
assembled plate was placed at 37°C (5% CO2,h u m i d i -
fied) for the duration of the migration time (2h). Once
the migration time had finished, media from the lower
and upper chambers were aspirated; migrated cells were
washed once in PBS without Ca
2+ and Mg
2+ ions and
the cells that had migrated to the other side of the
membrane were fixed with 100% pre chilled methanol
for 10 min. Cells were subsequently washed two times
in PBS and the non migrated cells on the top side of
the transwell membrane were swabbed using Q-tips.
The migrated cells were then stained by incubating in 5
μg/ml propidium iodide in PBS (600 μl/well) for 10
min. Cells were subsequently washed two times in PBS
and a microsurgery knife was used to cut out the trans-
well membrane. The membranes were placed on labeled
g l a s ss l i d e sw i t hm i g r a t e dc e l l sf a c i n gu p .Ad r o po f
Antifade Component A (Molecular Probes, Invitrogen,
Carlbad, CA) was placed on top of each membrane
prior to covering with a glass cover slip. Images of
migrated cells were captured by fluorescent microscopy
at six different fields/membrane at 100× magnification.
The migrated cells were counted using Image J NIH
software.
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Experimental data was subjected to statistical analysis
using the Analysis ToolPak in Microsoft Excel X for
Mac. Dose response data were subject to regression ana-
lysis and analysis of variance (ANOVA). Data from mul-
tiple treatments/conditions was subjected to ANOVA
followed by the Newman-Keuls multiple comparison t-
test routine. Differences between groups were consid-
ered statistically significant when p was less than 0.05.
Computational Model Development
In this paper we develop a model of VEGF binding and
regulation of cell surface binding by VEGFf (Figure 1,
Table 1). The model is based on mass-action kinetics
describing binding and cell surface trafficking interac-
tions for VEGF with VEGFR1, VEGFR2, NP-1, and
ECM sites and builds on previous work from Popel and
co-workers[15-20]. In the model, VEGF can form a triad
with VEGFR2 and NP-1 but not with VEGFR1. NP-1
can bind VEGFR1 in the absence of VEGF but not
VEGFR2. Coupling and uncoupling rates were consid-
ered equivalent for all species and independent of VEGF
binding. A 1:1 stoichiometry of VEGF to receptor or
NP-1 was maintained. Heparan sulfate proteoglycans
( H S P G s )w e r eo n l ye x p l i c i t l yi n c l u d e da sE C Ms i t e s .
Synthesis was based on steady-state receptor levels and
internalization rates for all species were considered
equivalent except where noted. The fluid phase is con-
sidered well-stirred.
Regulation of VEGF binding by VEGFf was investi-
gated in two ways. VEGFf has been shown previously to
bind to VEGFR1 with a similar affinity as VEGF, but
does not bind VEGFR2[14]. In this paper, we provide
evidence that VEGFf does not bind to NP-1 or ECM
sites. The model reflected these events but there is no
direct evidence supporting or excluding VEGFf bound
to VEGFR1 from interacting with NP-1 as shown for
VEGF121[10] but not VEGF. In model 1, VEGFf was
therefore able to bind VEGFR1 and then couple with
NP-1 or bind to VEGFR1-NP-1 complexes. In model 2,
binding of VEGFf to VEGFR1 excluded further interac-
tions with NP-1 and VEGFf was not able to bind to
VEGFR-NP-1 complexes. In all other ways the models
are identical.
The models are composed of a set of nonlinear ordin-
ary differential equations. The equations listed below
describe Model 2, where VEGFf bound to VEGFR1
excludes any interactions between VEGFR1 and NP-1.
Symbols are defined in Tables 1 and 2.
dCR1
dt
= kVR1
f VR1 − kVR1
r CR1 − kC
int CR1 (1)
dCR2
dt
= kVR2
f VR2 − kVR2
r CR2
−kC2N
c CR2N + kC2N
uc TV − kC
int CR2
(2)
dCE
dt
= kVE
f VE − kVE
r CE (3)
dCN
dt
= kVN
f VN − kVN
r CN − kCNR2
c CNR2
+kCNR2
uc TV − kC
int CN
(4)
dX
dt
= kR1N
c R1N − kR1N
uc X − kint X (5)
dR1
dt
= SR1 − kVR1
f VR1 + kVR1
r CR1 − kR1N
c R1N
+kR1N
uc X − kFR1
f FR1 + kFR1
r D − kint R1
(6)
dR2
dt
= SR2 − kVR2
f VR2 + kVR2
r CR2 − kCNR2
c CNR2
+kCNR2
uc TV − kint R2
(7)
dE
dt
= −kVE
f VE + kVE
r CE (8)
dN
dt
= SN − kVN
f VN + kVN
r CN − kR1N
c R1N
+kR1N
uc X − kC2N
f CR2N + kC2N
f TV − kint N
(9)
dD
dt
= kFR1
f FR1 − kFR1
r D − kF
int D (10)
dTv
dt
= kCNR2
c CR2N − kCNR2
uc TV + kC2N
c CR2N
−kC2N
uc TV − kC
int TV
(11)
Table 1 Model Reactions
VEGF VEGFf
R1 +V↔ CR1 Model 1&2
R2 + V ↔ CR2 R1 + F ↔ D
E+V↔ CE Model 1 only
N+V↔ CN D+N↔ TF
CR2 + N ↔ TV X+F↔ TF
CN + R2 ↔ TV
R1 + N ↔ X
V = VEGF, F = VEGFf, R1 = VEGFR1, R2 = VEGFR2, N = NP-1, E = ECM, CR1 =
VEGF-VEGFR1, CR2 = VEGF-VEGFR2, CE = VEGF-ECM, CN = VEGF-NP-1, D =
VEGFf-VEGFR1, TV = VEGF-VEGFR2-NP-1,TF = VEGFf-VEGFR1-NP-1, X = VEGFR1-
NP-1
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dV
dt
= −kVR1
f VR1 + kVR1
r CR1 − kVR2
f VR2 + kVR2
r CR2
−kVN
f VN + kVN
r CN − kVE
f + kVE
r CE
(12)
v
dF
dt
= −kFR1
f FR1 + kFR1
r D (13)
With Model 1 where VEGFf bound VEGFR1 can
interact with NP-1 the following equations are altered:
dX
dt
= kR1N
c R1N − kR1N
uc X − kFX
f FX + kFX
r TF − kint X (5b)
dD
dt
= kFR1
f FR1 − kFR1
r D − kD
c DN + kDN
uc TF − kF
int D (10b)
v
dF
dt
= −kFR1
f FR1 + kFR1
r D − kFX
f FX + kFX
r TF (13b)
and added:
dTF
dt
= kFX
f FX − kFX
r TF + kDN
c DN − kDN
uc TF − kF
int TF (14)
Simulations were run in Matlab R2006b (The Math-
works, Inc., Natick, MA) using the stiff ordinary differ-
ential equation solver ode15s with the backwards
differentiation formulas option and an absolute toler-
ance criteria of 1 × 10
-20. Parameter values are listed in
Table 2. Simulations were generally run for 3h. Values
were used as reported in the literature with no attempt
to adjust based on temperature.
Results
Elastase Degrades VEGF Binding Sites in the ECM
Elastase is known to degrade ECM components includ-
ing HSPGs [21-23], thus, we explored the possibility
that elastase degrades VEGF binding sites within the
ECM. To do this, we isolated ECM from rat smooth
muscle cell cultures, subjected these ECM preparations
to elastase digestion and then measured VEGF binding.
Previous studies have indicated that fibronectin is a
major VEGF binding site in the ECM. Thus, we also
investigated the possibility that elastase destroys VEGF
binding sites on fibronectin using polystyrene surfaces
coated with fibronectin. Elastase treatment of smooth
muscle cell-deposited ECM or fibronectin matrices
Table 2 Model Parameters*
Symbol Value Meaning
R1(t = 0) 65,000 #/cell # of VEGFR1 per cell at time zero
R2(t = 0) 12,000 #/cell # of VEGFR2 per cell at time zero
N(t = 0) 10,000 #/cell # of Neuropilin-1 per cell at time zero
E(t = 0) 1,000,000 #/cell # of ECM sites per cell which can bind
VEGF at time zero
kVR1
f ;kVR1
r 3×1 0
7 M
-1 s
-1;
1×1 0
-3 s
-1
Association/dissociation rate constant for
VEGF binding to VEGFR1
kVR2
f ;kVR2
r 1×1 0
7 M
-1 s
-1;
1×1 0
-3 s
-1
Association/dissociation rate constant for
VEGF binding to VEGFR2
kVE
f ;kVE
r 4.2 × 10
5 M
-1 s
-1;
1×1 0
-2 s
-1
Association/dissociation rate constant for
VEGF binding to ECM (based on HS values from literature)
kVN
f ;kVN
r 3.125 × 10
6 M
-1 s
-1;
1×1 0
-3 s
-1
Association/dissociation rate constant for
VEGF binding to NP-1
kFR1
f ;kFR1
r 3×1 0
7 M
-1 s
-1;
1×1 0
-3 s
-1
Association/dissociation rate constant for
VEGFf binding to VEGFR1(modeled the same as VEGF)
kC2N
c ;kC2N
uc 3.1 × 10
13 (mol/cm
2)
-1 s
-1;
1×1 0
-3 s
-1
Coupling/uncoupling rate constant for
VEGF-VEGFR2 with NP-1
kR1N
c ;kR1N
uc 1×1 0
14 (mol/cm
2)
-1 s
-1;
1×1 0
-2 s
-1
Coupling/uncoupling rate constant for
VEGFR1 with NP-1
kCNR2
c ;kCNR2
uc 1×1 0
14 (mol/cm
2)
-1 s
-1;
1×1 0
-3 s
-1
Coupling/uncoupling rate constant for
VEGF-NP-1with VEGFR2
kFX
f ;kFX
r kFR1
f ;kFR1
r Association/dissociation rate constant for
VEGFf binding to VEGFR1-NP-1
kDN
c ;kDN
uc kR1N
c ;kR1N
uc Coupling/uncoupling rate constant for
VEGFf-VEGFR1 with NP-1
kint 2.8 × 10
-4 s
-1 Internalization rate for unbound receptors
kC
int 2.8 × 10
-4 s
-1 Internalization rate for VEGF-bound receptors
kF
int 2.8 × 10
-4 s
-1 Internalization rate for VEGFf-bound receptors
SI kintI0 Synthesis rate for species I where I0 is the initial concentration of I
*Values are from literature when possible [20]. VEGFf assumed to interact in similar manner to VEGF when applicable.
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(Figure 2). Approximately 50% loss in binding was
observed with 5 and 1 μg/ml elastase treatments of
ECM and fibronectin respectively, while high doses of
elastase (50 μg/ml) resulted in >90% loss of binding to
either matrix. Therefore, elastase treatment at concen-
trations that have previously been shown to cause
growth factor release from ECM [21-23] would be pre-
dicted to cause a loss of VEGF binding sites within the
ECM.
Simulations Indicate ECM Sites Have Minimal Impact on
VEGF binding to Cell Surface Receptor
ECM sites for VEGF are generally numerous but of low-
affinity [15,24]. Using our VEGF model (Table 1,
described in Methods), we investigated how the density
of ECM sites impacted VEGF receptor binding using
simulations. VEGF (0.023 nM) was added at time zero
and the levels of VEGF-VEGFR1 and VEGF-VEGFR2
complexes were determined after three hours of simula-
tion time (Figure 3). Under these conditions (Table 2),
there was considerable retention (surface and interna-
lized complexes) of VEGF to both VEGFR1 and
VEGFR2 with over five times as many VEGFR1 com-
plexes as VEGFR2 complexes across the range of ECM
density investigated. Similar results were found when we
looked at just surface complexes at 3 h instead of total
complexes (surface and internalized) or when internali-
zation and synthesis were eliminated in simulations of
4°C binding data (data not shown). These different
binding levels were a consequence of the higher density
of VEGFR1 and the higher binding affinity of VEGF for
this receptor (Table 2). The density of ECM sites had a
negligible effect on VEGF binding to either VEGFR1 or
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Figure 2 Pre-treatment of fibronectin and SMC-derived ECM with NE decreases VEGF binding. A: 96-well hydrophobic plates were coated
with 10 μg/ml fibronectin in the presence of 10 μg/ml heparin. Plates were treated with NE then
125I-VEGF (0.45 nM) was added for 2 h. Bound
VEGF was released with 2 M NaCl, 25 mM HEPES, pH 7.5. B: Primary rat smooth muscle cells were grown 5 days past confluence, cell layer
dissolved, and the exposed extracellular matrix was incubated with NE. ECM coated wells were then incubated with
125I-VEGF (0.45 nM) and
bound VEGF extracted. Each data point is the mean of quadruplicate determinations ± SEM. Regression analyses with ANOVA of both dose
response curves revealed a statistically significant effect of NE treatment with Significance F and p values below 0.05.
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Figure 3 ECM Density Impacts Receptor Binding of VEGF at
High Densities. Simulation results following introduction of VEGF
(0.023 nM or 1 ng/ml) at time zero. VEGF retained by VEGFR1
(open) or VEGFR2 (filled) after 3 h of VEGF exposure is shown. All
other parameter values were at base values (Table 2) except for
ECM site density.
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7 sites/cell
where inhibition becomes significant. This is due to the
low affinity of these sites for VEGF compared to
VEGFR1 or VEGFR2. If the affinity of the ECM site is
significantly higher, the effect would be greater (data not
shown). At typical cell densities measured in cultures
(10
6 sites/cell and lower) and affinities, degradation of
ECM sites would not be predicted to have a significant
effect on receptor binding of VEGF and would therefore
be unlikely to impact cell activity.
VEGF fragment Exhibits Negligible Binding to ECM,
Fibronectin and Neuropilin-1
We have shown, however, that the impact of elastase
with regard to the VEGF system is not limited to the
ECM binding sites. Elastase cleaves VEGF to produce a
smaller fragment of VEGF (VEGFf) with cleavage sites
at the C-terminal, N-terminal and internal regions that
exhibits reduced binding to heparin and VEGFR2 but
retains the ability to bind VEGFR1[14]. We therefore
tested whether VEGFf bound to cell-deposited ECM.
VEGF bound ECM in a dose-dependent manner (Figure
4A) while VEGFf exhibited negligible binding indicating
that the conversion to VEGFf would likely impact ECM
storage of the growth factor.
In related studies, we found that heparin exposure sig-
nificantly increases VEGF binding to fibronectin catalyz-
ing the conversion of fibronectin to an open
conformation [24,25]. Thus, to more fully characterize
the effects of elastase on VEGF activity, we prepared
VEGFf and assessed its binding to fibronectin ± heparin.
Fibronectin ± heparin was adsorbed on hydrophobic
polystyrene surfaces and
125I-VEGF and
125I-VEGFf
binding measured. Intact VEGF showed minimal bind-
ing to fibronectin in the absence of heparin exposure
but showed significantly enhanced binding to fibronectin
that was previously incubated with heparin (Figure 4B).
This heparin-enhanced VEGF binding was 5 to 14 fold
higher compared to VEGF binding to fibronectin alone
over the range of VEGF concentrations tested. In con-
trast, VEGFf showed no significant binding to fibronec-
tin in the presence or absence of heparin. The lack of
VEGFf binding to fibronectin is consistent with an over-
all reduced ability to bind to ECM binding sites as com-
pared to intact VEGF.
NP-1 is a co-receptor for VEGF that enhances angio-
genic signaling cooperatively with VEGFR2. Therefore
we examined whether VEGFf was able to bind to NP-1
and if this interaction would influence interactions with
V E G F R 1 .T od os o ,w ep e r f o r m e dc e l l - f r e er e c e p t o r
binding experiments using Fc-NP-1 and Fc-VEGFR1
chimeric proteins. The chimeras were composed of the
extracellular VEGF bindingd o m a i no ft h er e l e v a n t
receptor fused to the Fc-region of human IgG1 via a
peptide linker.
125I-VEGF or
125I-VEGFf was incubated
with Fc-NP-1, Fc-VEGFR1 or both for 2h. Bound com-
plexes were measured after pull down with magnetic
protein A beads. VEGFf showed no significant binding
to Fc-NP-1 chimera at either concentration tested (0.25
or 1 nM) while intact VEGF bound Fc-NP-1 (Figure 4C)
indicating that elastase processing of VEGF alters its
ability to bind NP-1. Previous studies have reported that
NP-1 is able to inhibit VEGF binding to VEGFR1 by
potentially heterodimerizing with VEGFR1 and prevent-
ing VEGF-VEGFR1 binding. To test whether VEGFf
binding to VEGFR1 is affected by the presence of NP-1,
Fc-VEGFR1 chimeras were pre-incubated with NP-1
prior to evaluating VEGF/VEGFf binding. Intact VEGF
bound to both Fc-VEGFR1 and Fc-NP-1 but the combi-
nation value was below that for Fc-VEGFR1 alone indi-
cating no additive effect for the combination and
suggesting that VEGFR1 interactions with VEGF were
reduced by the presence of NP-1 (Figure 4D). VEGFf
bound to Fc-VEGFR1 but not Fc-NP-1 and the addition
of Fc-NP-1 had a negligible impact on VEGFf overall
binding. This suggests that either (1) VEGFf binding to
VEGFR1 is unaffected by NP-1 and that there is no dif-
ference in VEGFf affinity for VEGFR1 alone or
VEGFR1-bound to NP-1 or that (2) VEGFf binding to
Fc-VEGFR1 inhibits VEGFR1 binding to NP-1 and that
the VEGFf interaction is of a higher affinity than the
VEGFR1-NP-1 interaction. In either case, these results
suggest that the inability of VEGFf to bind NP-1 is
reflective of a general loss of NP-1 control over the sys-
tem. We decided to investigate how these two possibili-
ties for VEGFf interactions with VEGFR1 and NP-1
would be predicted to impact the VEGF system using
computational modeling.
Computational Model Shows that VEGF Fragment Impacts
VEGF-VEGFR2 Complex Levels Despite Not Binding to
VEGFR2
A computational model including VEGF, VEGFR1,
VEGFR2, NP-1 and VEGFf was developed. In our
model, VEGFf is able to bind VEGFR1 with the same
affinity as does VEGF but it is not able to bind either
VEGFR2 or NP-1. Our experimental results, however,
were unclear regarding VEGFf interactions with
VEGFR1-NP-1 complexes and so we investigated this
question using two variations of the model. In Model 1,
VEGFf can bind to VEGFR1-NP-1 complexes and
VEGFf bound to VEGFR1 can bind to NP-1, similar to
VEGF121[10]. In Model 2, VEGFf binding to VEGFR1
excludes interactions between VEGFR1 and NP-1
entirely. With Model 2, there are no VEGFf-VEGFR1-
NP-1 complexes. In the simulations, VEGF (1 ng/ml;
0.023 nM) and VEGFf were both added at time zero
and simulations run corresponding to three hours of
Forsten-Williams et al. BMC Systems Biology 2011, 5:170
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Page 7 of 15experimental incubation. These conditions might corre-
spond to the case where VEGFf has been generated
from matrix-bound VEGF by elastase and the VEGFf is
now soluble and capable of impacting VEGF binding
downstream.
Using our model, in the absence of VEGFf, there was
greater than five times more VEGF-VEGFR1 complexes
than VEGF-VEGFR2 complexes due to the increased
affinity and density of VEGFR1 (Figure 5). The addition
of VEGFf reduced VEGF-VEGFR1 complexes with both
Model 1 and Model 2 to a similar extent. VEGFf com-
petes directly with VEGF for binding to VEGFR1 and so
increasing the concentration of VEGFf resulted in an
expected reduction in VEGF-VEGFR1 complexes. In
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-VEGFf (filled) was incubated for 3 hours at 4°C and bound growth factor was determined. Significant differences between VEGF and VEGFf
binding was found. B: VEGF/VEGFf binding to fibronectin ± heparin.
125I-VEGF (circles) or
125I-VEGFf (diamonds) bound to fibronectin alone
(open) or with heparin (filled). C: VEGF/VEGFf binding to NP-1.
125I -VEGF or
125I -VEGFf at 0.25 (filled) and 1 (open) nM were incubated with Fc-
NP-1 for 2 h and complexes determined. Significant differences were found between VEGF bound in the presence of 0.5 nM NP-1 compared to
no NP-1, and with 0.25 nM VEGF in the presence of 0.1 nM NP-1 compared to no NP-1. No significant differences were noted for VEGFf ± NP-1.
D: VEGF/VEGFf binding to VEGFR1 and NP-1. 0.25 nM
125I -VEGF or
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Fc-NP-1 (0.5 nM, light grey), or both VEGFR1 and NP-1 (black) for 2 h; complexes were pulled down and
125I-VEGF/VEGFf counted. Significant
differences were observed with all VEGF bound groups, and between VEGFf bound in the presence versus the absence of VEGFR1. No significant
difference was noted between VEGFf bound to VEGFR1 ± NP-1. Data are the mean of quadruplicate (A,C) triplicate (D) or duplicate (B)
determinations ± SD. ANOVA followed by multi-comparison t-tests was performed for statistical analysis.
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Page 8 of 15contrast, the effect of VEGFf on VEGF binding to
VEGFR2 was markedly different depending on whether
VEGFf binding to VEGFR1 excluded interactions with
NP-1.
With Model 1 (Figure 5A), where NP-1 can interact
with VEGFf-VEGFR1 complexes, even the addition of
high concentrations of VEGFf had only a small but posi-
tive effect (< 2%) on the level of VEGF retained by
VEGFR2 (bound + internalized) (Figure 5A). In contrast,
when VEGFf binding inhibits interactions between
VEGFR1 and NP-1 (Model 2), addition of fragment
more than doubled the level of VEGF retained by
VEGFR2 (Figure 5B). The total amount of VEGF
retained by the cells in the presence of VEGFf reflects
these differences in VEGFR2 binding with Model 1
showing only inhibition while Model 2 showed a bipha-
sic response. Similar relative results were found when
looking at surface bound only (excluding internalized
complexes) or when synthesis and internalization were
excluded from the model (results not shown).
Neuropilin Sequestration Impacts VEGF-VEGFR2 Complex
Levels
The difference in VEGF-VEGFR2 complexes in response
to VEGFf between the two models was striking. When
we looked at the level of VEGFR1 that was not bound
to VEGF, VEGFf or NP-1, we found that these levels
decreased with increasing VEGFf until there were essen-
tially no free VEGFR1 with either Model (Figure 6A). In
contrast, VEGFR1 bound to NP-1 was not significantly
altered by the presence of VEGFf with Model 1, yet was
dramatically reduced with Model 2. This reduction in
VEGFR1-NP-1 complexes in Model 2, as a result of the
binding of VEGFf to VEGFR1 and the subsequent exclu-
sion of NP-1 from the VEGFR1-NP-1 complex, leads to
an increase in NP-1 available for VEGF-VEGFR2 stabili-
zation. This stabilization leads to increased VEGFR2
complexes and resulting increased total retention of
VEGF found with Model 2, as the increase VEGFR2
binding is greater than the loss of VEGFR1 binding in
these simulations (Figure 5B).
NP-1 levels had a critical impact on VEGF retention
by VEGFR2 (Figure 6B). Despite having an equivalent
level of VEGF, higher levels of NP-1 resulted in near
saturation of binding and a more than 5 fold increase in
binding levels over that at the lowest level of NP-1.
Model 2 enhances VEGF-VEGFR2 levels over the lower
range of NP-1 values investigated compared to both
VEGF-VEGFR2 levels with Model 1 as well as to the
situation when VEGF-VEGFR2 binding occurs in the
absence of VEGFf (control case). Note that VEGF-
VEGFR2 retention in the absence of VEGFf (control
case) is the same for Model 1 and Model 2 since the dif-
f e r e n c eb e t w e e nt h em o d e l sl i e so n l yi nt h eb i n d i n go f
VEGFf.
Coupling Between VEGFR1 and NP-1 Regulates VEGF-
VEGFR2 Binding
The importance of the NP-1 levels as well as the differ-
ences observed with the two VEGFf binding models sug-
gest that coupling between VEGFR1 and NP-1 is critical
to regulation of VEGF-VEGFR2 binding both in the pre-
sence or absence of VEGFf. In the absence of coupling
between the two surface proteins (VEGFR1 and NP-1),
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Figure 5 Impact of VEGFf on VEGF-Receptor binding differs
when VEGFf interacts with VEGFR1 and NP-1. Simulation results
for (A) Model 1 (VEGFf can bind to VEGFR1 and NP-1) and (B) Model
2 (VEGFf cannot bind to VEGFR1 and NP-1) 3 h after introduction of
VEGF(1 ng/ml or 0.023 nM) and VEGFf to the cell system. VEGF
bound to VEGFR1 (open), VEGFR2 (filled), and sum of VEGF bound
to VEGFR1, VEGFR2, NRP, and ECM (solid line)
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Page 9 of 15VEGFf had an impact (~15%) on VEGF retention by
V E G F R 2( F i g u r e7 ,k c=0 ) .T h i si m p a c tw a ss i g n i f i -
cantly decreased (~3%) when endocytosis/synthesis was
not included (data not shown). At our baseline coupling
v a l u e( k c 0 ,T a b l e2 ) ,V E G Fb i n d i n gt oV E G F R 2w a s
decreased compared to that found in the absence of
coupling (kc = 0) for both models, but it increased by
approximately 3-fold when VEGFf was added for Model
2 (large filled dots). At the highest VEGFf value, the
amount of VEGF retained by VEGFR2 is the same as
that found in the absence of coupling (kc = 0) for
Model 2. Decreasing the coupling value increases the
percentage of VEGF-bound VEGFR2 while increasing
the coupling value had the opposite effect. VEGFf had a
smaller impact on the retention of VEGF by VEGFR2
with Model 1 irrespective of the coupling rate (dotted
lines in Figure 7). This impact was negligible when
endocytosis/synthesis was not included (data not
shown). Looking only at surface bound VEGF-VEGFR2
showed similar trends to that shown in Figure 7 (data
not shown).
Relative Receptor Levels and Receptor-Mediated
Endocytosis Impact VEGF Capture
Our model assumed that endocytosis was equivalent for
receptors regardless of receptor occupancy. However,
many ligand-receptor systems show enhanced endocyto-
sis when ligand is bound. Thus, we tested how varying
the relative endocytosis rates would impact VEGF-
VEGFR2 retention. As shown in Figure 8, increasing the
rate of endocytosis for VEGF-bound receptors resulted
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Page 10 of 15in a significant increase in VEGF-VEGFR2 retention
while reducing that rate lead to an overall reduction in
VEGF-VEGFR2 retention. How these differences might
influence signaling however is unclear. Retention
includes all VEGF-VEGFR2 complexes (internal and cell
surface). If one looked only at surface interactions at 3
hr, the opposite results would be found (data not
shown). At 100 times the baseline internalization rate
(100*kint), there are essentially no complexes on the
surface while at the reduced internalization rate
(0.01*kint) there was essentially no internalized com-
plexes with all VEGF-VEGFR2 being on the cell surface.
We further explored the role of receptor levels by varying
the levels of VEGFR1, VEGFR2, and NP-1. For example,
recent work has suggested that receptor levels may be
much lower than NP-1 levels in certain cells [26]. Setting
all levels to 12,000 sites per cell, we found that VEGFf
resulted in increased VEGF-VEGFR2 retention by cells
with Model 2 but only a small decrease with Model 1 (Fig-
ure 8B). Increasing the levels of VEGFR1 or VEGFR2
resulted in a change in the retention levels but the overall
trend of increasing binding with VEGFf for Model 2 only
was found. Increasing NP-1 levels essentially eliminated the
effect of VEGFf on VEGFR2 retention, further illustrating
the importance of this component for VEGFf activity.
Conversion of VEGF to VEGFf affects Cell Migration
NE action on the VEGF system would be predicted to
cause a reduction in VEGF binding sites in the ECM and
the conversion of VEGF to VEGFf. Simulations indicated
that the loss of ECM sites would likely have a negligible
effect under standard cell culture conditions and so we
focused on evaluating the effect of VEGF conversion to
VEGFf. Stimulation of endothelial cell migration is a hall-
mark of VEGF treatment and is thought to reflect a key
component of VEGF’s biological function [1]. Thus, we
conducted experiments to evaluate whether VEGFf
impacted this process. Endothelial cells were plated on
microporous transwell inserts and VEGF, VEGFf, or
combinations of the two were introduced into the lower
chamber. Endothelial cells did not migrate in response to
VEGFf alone (p = NS) while showing a strong migratory
r e s p o n s ea f t e r2ht oV E G F( F i g u r e9 ) .C o m b i n a t i o n so f
VEGF and VEGFf showed a biphasic response with 25%
VEGFf and 75% VEGF leading to a statistically significant
increased response compared to 100% VEGF while
higher ratios of VEGFf led to a diminished response, a
not necessarily straightforward result.
A Simple Increase in VEGF-VEGFR2 is Not Likely
Responsible for VEGFf-mediated Enhanced Cell Migration
To evaluate various possible mechanisms for the
enhanced cell migration observed when portions of
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Page 11 of 15VEGF were substituted with VEGFf, simulations were
performed for 2 h where the sum of VEGF and VEGFf
added was kept constant (0.45 nM) such that at high
VEGF concentrations there are low VEGFf levels and at
low VEGF concentrations there are high VEGFf concen-
trations. These conditions might simulate a situation
where there is both VEGF and VEGFf entering a cell
environment due to local conversion of VEGF to VEGFf
by NE rather than the case where excess VEGFf enters a
cell environment. VEGFR1, VEGFR2, and NP-1 were all
set to the same value (12,000 #/cell). As shown in Figure
10A, with both Models the conversion of VEGF to
VEGFf resulted in a reduction in VEGF-VEGFR2 com-
plexes. Even with Model 2, where VEGFf binding to
VEGFR1 releases NP-1 for VEGF-VEGFR2 complex sta-
bilization, the reduction in available VEGF for binding
to VEGFR2 as a result of conversion to VEGFf is not
compensated for by NP-1-mediated stabilization. Simi-
larly, VEGF-VEGFR1 complexes are also reduced by the
conversion of VEGF to VEGFf in both cases.
Signaling by VEGFf is one Possible Mechanism
There is evidence that VEGF signaling can occur
through both VEGFR1 and VEGFR2 and that some type
of interplay or balance between the two may be at work.
For example, we recently showed that VEGF stimulates
phosphorylation of both ERK1/2 and Akt in endothelial
cells while VEGFf addition resulted in strong phosphor-
ylation of Akt but not ERK1/2[14]. Looking at VEGFR1
binding, we find with Model 1 an increase in complex
formation (VEGF + VEGFf) while Model 2 shows a
decrease in total VEGFR1 complexes (Figure 10B). This
difference reflects the binding of VEGFf to VEGFR1-
NP-1 complexes permissible with Model 1. NP-1 has
been shown to have a role in VEGF signaling and to
alter VEGFR2 signaling [27-29]. We therefore looked at
how the combined signaling potential of VEGF and
VEGFf through NP-1 in our simulations might proceed
as one possible mechanism (Figure 10C). With Model 1,
VEGF conversion to VEGFf led to a very strong increase
in the total amount of VEGFf-VEGFR1-NP-1 complexes.
This counterbalanced the decrease in VEGF-VEGFR2-
NP-1 complexes resulted in a combined “total” that was
biphasic. In contrast, Model 2 does not allow for VEGF-
VEGFR1-NP-1 complexes resulting in only a decreasing
VEGF-VEGFR2-NP-1 “signal”.
Discussion
VEGF has long been recognized as an endothelial cell
survival factor and mitogen as well as having a role in
endothelial cell migration and vessel repair. There are
multiple VEGF isoforms with VEGF165,ah e p a r i n - b i n d -
ing variant, being the most widely expressed in vivo.W e
have recently observed that neutrophil elastase can
cleave VEGF and generate VEGFf, a biologically-active
fragment of VEGF with altered receptor binding and
activity [14]. Unlike several of the other proteolytically
processed forms of VEGF, which generally involve trun-
cation of the primary VEGF polypeptide chain [27-29],
NE appears to cleave the VEGF chain within internal
regions in addition to the termini. In this way, VEGFf is
held together by intra- and inter-chain disulfide bonds
and shows interesting features resulting from selective
alterations in its binding properties. The present paper
focuses on coupling computer simulations with experi-
mental studies to delve further into the impact of NE
on the VEGF network in order to gain insight on the
larger question of how proteolytic damage to growth
factor-laden tissues during injury and inflammation
might modulate bioavailability and activity.
Enzymatic processing of the extracellular matrix, a
depository site for important biological molecules, can
result in the release of stored growth factors thereby
increasing their availability for activity. In addition, the
degradation of the ECM may alter its ability to capture
additional growth factors. We show this to be the case
with NE and VEGF. Treatment of both surface-depos-
ited fibronectin and cell-derived ECM with NE resulted
in a significant decrease in VEGF binding (Figure 2).
We postulated that elastase damage to ECM might
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were seeded on the upper membrane of transwell cell migration
chambers. VEGF and VEGFf were added to the lower chamber in
various ratios, with the total amount of VEGF/VEGFf combination or
alone being 0.45 nM. The cells were incubated for 2 h at 37°C.
Migrated cells were fixed, stained with propidium iodide and
images collected by a fluorescent microscope (100 × magnification).
Each representative image showed one sixth of the field and were
used for quantification. The average cell number migrated ± SEM of
12 fields per condition; n = 3. ANOVA followed by the multi-
comparison t-tests revealed significant differences between all
groups except the no VEGF “Control” and the all VEGFf “0:1.0”
conditions.
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Page 12 of 15result in increased cellular VEGFR binding due to a
reduction in competition from the ECM sites. Using
simulations, however, we found that the impact was
negligible unless the sites were of very high number or
high affinity (comparable or better than the receptors
for VEGF, data not shown) (Figure 3). While the effect
of ECM competition was negligible under the in vitro
cell culture conditions used in our study, it is likely that
this process would be very relevant in matrix-rich tis-
sues in vivo where VEGF is stored and binding sites are
abundant such as in the lung and blood vessel wall.
Under those conditions, our simulations suggest that
degradation of sites would have a major impact on
VEGF availability for receptor binding.
Our studies suggest that a more important conse-
quence of NE treatment with regard to the VEGF sys-
tem may be the conversion of VEGF to VEGFf.
Simulations demonstrate that the presence of VEGFf,
with its altered binding properties compared to VEGF,
could have a significant impact on VEGF receptor
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VEGF-VEGFR2-NP-1 complexes (Model 1-open square), VEGF-VEGFR1-NP-1 (Model 1 - open triangle), and the sum of VEGF-VEGFR1-NP-1 and
VEGF-VEGFR2-NP-1 complexes (Model 1 -open circle, Model 2 - filled circle). Note that there are no VEGF-VEGFR1-NP-1 complexes with Model 2.
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Page 13 of 15binding. Previously we have shown that VEGFf does not
bind to VEGFR2 [14] and data included herein show a
loss of binding to NP-1 as well as to fibronectin (Figure
4). We postulated that VEGFf addition would result in
increased VEGF binding to VEGFR2 due to a reduction
in VEGF-VEGFR1 complexes as a simple consequence
of VEGFf-VEGFR1 binding. Using simulations, however,
we find that VEGFf can impact VEGF receptor interac-
tions in a more complex manner (Figure 5). When
VEGFf binding to VEGFR1 did not prevent VEGFR1
interactions with NP-1 or VEGFf was able to bind to
VEGFR1 bound to NP-1 (Model 1), VEGFf did not
increase overall VEGF binding to VEGFR2 and had only
a limited effect. In contrast, when VEGFf binding to
VEGFR1 prevented VEGFR1 interactions with NP-1
(Model 2), VEGFf essentially acted as a release mechan-
ism for the VEGF-VEGFR2 stabilizer, NP-1, and
increased VEGF interactions with VEGFR2 were evident.
The role of VEGFf appears therefore to be more of an
indirect regulator of VEGF through NP-1 than a direct
regulator of VEGF-receptor interactions. This was illu-
strated further by looking at the impact of NP-1 density
(Figure 6) and the coupling rate between NP-1 and
VEGFR1 (Figure 7). This type of ternary regulation is
not unique to the VEGF system. Many heparin-binding
growth factors, such as fibroblast growth factor -2 (FGF-
2), form stabilizing complexes with cellular receptors
and HSPGs, resulting in significant enhancement of
receptor activation. Certainly receptors such as gp130
have been shown to play an important role in cytokine
signaling within a number of systems making it a poten-
tially more important system regulator than any indivi-
dual component. This ternary complex regulation may
also have a role in heterodimerization and cross-talk
within (i.e., VEGFR1-R2 heterodimers) and between
g r o w t hf a c t o rs y s t e m ss u c ha sw h a ti ss u g g e s t e df o rt h e
IGF-I and EGF families [30].
Our original hypothesis was that elastase conversion
of VEGF to VEGFf would result in the generation of a
non-stimulating form of the growth factor due to its
inability to bind the major signaling receptor VEGFR2.
Both our experimental and simulation results suggest
that this model is an oversimplification of this complex
ligand-receptor system. VEGF alone stimulates endothe-
lial cell migration while VEGFf alone does not (Figure
9). Conversion of VEGF to VEGFf should result in
increased VEGFf and decreased VEGF with the same
overall concentration of total growth factor to be found.
With cell migration studies designed to test this effect,
we found an increase in migration when the VEGF con-
centration was reduced by 25% with a corresponding
substitution of VEGFf, in contrast to what one might
expect based on the results with 100% VEGF and 100%
VEGFf. Further increases in VEGFf beyond 25% and
corresponding decreases in VEGF resulted in reduced
migration. Simulations showed that this biphasic
response could not be explained simply by an increase
and then decrease in VEGF binding to VEGFR2 caused
by VEGFf addition (Figure 10) regardless of whether
VEGFf bound to VEGFR1-NP-1 complexes or not.
There is however evidence that NP-1 [7] and VEGFR1
are also involved in VEGF signaling [31] and may be
involved in mediating the migration process. Previously
we found that Akt but not ERK 1/2 was activated by
VEGFf suggesting that this key signal pathway might be
mediated through VEGFR1 [14]. Using simulations, we
find that under conditions where the total VEGF plus
VEGFf remains constant, VEGF binding to VEGFR1 and
VEGFR2 is reduced while VEGFf binding to VEGFR1 is
increased (Figure 10). Further, when one focuses on NP-
1s t a b i l i z e dV E G Fa n dV E G F fc o m p l e x e s ,w ef i n dt h a t ,
with Model 1, a biphasic binding situation exists with a
peak sum of VEGF-VEGFR2-NP-1 and VEGF-VEGFR1-
NP-1 at an intermediate combination of VEGF and
VEGFf. Certainly this is not direct evidence but simply
further illustrates how NP-1 might be critical to the reg-
ulation of VEGF-VEGFf activity. Further experimental
studies are needed to determine exact mechanisms but
our simulations suggest possibilities worth exploring
with regard to NP-1. There are also recent reports indi-
cating that VEGFR1 and VEGFR2 can form heterodi-
mers [32]. Thus, VEGFf also has the potential to
influence the formation of these complexes directly and
through NP-1 interactions. As experimental data
become available it will be interesting to explore these
additional aspects of the system to fully appreciate how
its complexity can be used to produce sophisticated
modes of regulation.
Conclusions
W eh a v es h o w nt h a tV E G F f ,a ne l a s t a s e - g e n e r a t e dp r o -
duct of VEGF, has a biphasic impact on VEGF stimu-
lated migration and, using simulations, we postulate that
this effect is via VEGFf-mediated VEGFR1 stimulation.
Simulations suggest that VEGFf activity is controlled by
its interactions with NP-1 and VEGFR1 and that release
or restriction of NP-1 controls whether enhanced VEGF
binding of VEGFR2 is likely to occur. Further experi-
mental studies targeted at testing the simulation predic-
tions are necessary to fully understand the complex
mechanisms controlling VEGF-signaling. Moreover,
these studies suggest that simulations can be a valuable
means to interpreting the complexity of perturbations
within a complex multi-receptor system and highlight
the need for quantitative parameter measurements to
obtain mechanistic understanding.
Forsten-Williams et al. BMC Systems Biology 2011, 5:170
http://www.biomedcentral.com/1752-0509/5/170
Page 14 of 15Acknowledgements and Funding
This work was supported in part by NIH grant HL088572 and by a
departmental grant from the Massachusetts Lions Eye Research Fund, Inc.
We thank Celeste B. Rich for providing primary rat smooth muscle cells and
pulmonary fibroblasts.
Author details
1Department of Chemical Engineering, Virginia Polytechnic Institute & State
University Blacksburg, VA 24061, USA.
2Department of Biochemistry, Boston
University School of Medicine, Boston, MA, USA.
3Departments of
Biochemistry & Ophthalmology, Boston University School of Medicine,
Department of Biomedical Engineering, Boston University, Boston, MA, USA.
Authors’ contributions
KFW developed and performed the computational simulations. EK
performed the experimental studies. MAN was involved in experimental and
simulation design as well as data analysis. All authors read and approved the
final manuscript.
Received: 16 May 2011 Accepted: 21 October 2011
Published: 21 October 2011
References
1. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors.
Nat Med 2003, 9:669-676.
2. Ferrara N: Vascular endothelial growth factor: basic science and clinical
progress. Endocr Rev 2004, 25:581-611.
3. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M,
Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J,
Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development
and lethality in embryos lacking a single VEGF allele. Nature 1996,
380:435-439.
4. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-
Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality
induced by targeted inactivation of the VEGF gene. Nature 1996,
380:439-442.
5. Tang K, Rossiter HB, Wagner PD, Breen EC: Lung-targeted VEGF
inactivation leads to an emphysema phenotype in mice. J Appl Physiol
2004, 97:1559-1566.
6. Neufeld G, Kessler O, Herzog Y: The interaction of Neuropilin-1 and
Neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol
2002, 515:81-90.
7. Kawamura H, Li X, Goishi K, van Meeteren LA, Jakobsson L, Cebe-Suarez S,
Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, Klagsbrun M, Claesson-
Welsh L: Neuropilin-1 in regulation of VEGF-induced activation of
p38MAPK and endothelial cell organization. Blood 2008, 112:3638-3649.
8. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML,
Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-
deficient mice. Nature 1995, 376:62-66.
9. Rahimi N: VEGFR-1 and VEGFR-2: two non-identical twins with a unique
physiognomy. Front Biosci 2006, 11:818-829.
10. Fuh G, Garcia KC, de Vos AM: The interaction of neuropilin-1 with
vascular endothelial growth factor and its receptor flt-1. J Biol Chem
2000, 275:26690-26695.
11. Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, Peale F, Bagri A, Tessier-
Lavigne M, Koch AW, Watts RJ: Neuropilin-1 binds to VEGF121 and
regulates endothelial cell migration and sprouting. J Biol Chem 2007,
282:24049-24056.
12. Hynes RO: The extracellular matrix: not just pretty fibrils. Science 2009,
326:1216-1219.
13. Rhodes JM, Simons M: The extracellular matrix and blood vessel
formation: not just a scaffold. J Cell Mol Med 2007, 11:176-205.
14. Kurtagic E, Jedrychowski MP, Nugent MA: Neutrophil elastase cleaves
VEGF to generate a VEGF fragment with altered activity. Am J Physiol
Lung Cell Mol Physiol 2009, 296:L534-L546.
15. Mac Gabhann F, Popel AS: Interactions of VEGF isoforms with VEGFR-1,
VEGFR-2, and neuropilin in vivo: a computational model of human
skeletal muscle. Am J Physiol Heart Circ Physiol 2007, 292:H459-H474.
16. Mac Gabhann F, Popel AS: Model of competitive binding of vascular
endothelial growth factor and placental growth factor to VEGF receptors
on endothelial cells. Am J Physiol Heart Circ Physiol 2004, 286:H153-H164.
17. Mac Gabhann F, Popel AS: Differential binding of VEGF isoforms to VEGF
receptor 2 in the presence of neuropilin-1: a computational model. Am J
Physiol Heart Circ Physiol 2005, 288:H2851-H2860.
18. Mac Gabhann F, Popel AS: Dimerization of VEGF receptors and
implications for signal transduction: a computational study. Biophys
Chem 2007, 128:125-139.
19. Wu FT, Stefanini MO, Gabhann FM, Kontos CD, Annex BH, Popel AS:
Computational kinetic model of VEGF trapping by soluble VEGF
receptor-1: effects of transendothelial and lymphatic macromolecular
transport. Physiol Genomics 2009, 38:29-41.
20. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS: A compartment model of
VEGF distribution in blood, healthy and diseased tissue. BMC Syst Biol
2008, 19:77.
21. Buczek-Thomas JA, Chu CL, Rich CB, Stone PJ, Foster JA, Nugent MA:
Heparan sulfate depletion within pulmonary fibroblasts: implications for
elastogenesis and repair. J Cell Physiol 2002, 192:294-303.
22. Buczek-Thomas JA, Lucey EC, Stone PJ, Chu CL, Rich CB, Carreras I,
Goldstein RH, Foster JA, Nugent MA: Elastase mediates the release of
growth factors from lung in vivo. Am J Respir Cell Mol Biol 2004,
31:344-350.
23. Buczek-Thomas JA, Nugent MA: Elastase-mediated release of heparan
sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism
for basic fibroblast growth factor (bFGF) release and attenuation of bfgf
binding following elastase-induced injury. J Biol Chem 1999,
274:25167-25172.
24. Mitsi M, Hong Z, Costello CE, Nugent MA: Heparin-mediated
conformational changes in fibronectin expose vascular endothelial
growth factor binding sites. Biochemistry 2006, 45:10319-10328.
25. Mitsi M, Forsten-Williams K, Gopalakrishnan M, Nugent MA: A catalytic role
of heparin within the extracellular matrix. J Biol Chem 2008,
283:34796-34807.
26. Imoukhuede PI, Popel AS: Quantification and cell-to-cell variation of
vascular endothelial growth factor receptors. Exp Cell Res 2011,
317:955-965.
27. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of
VEGF bioavailability by genetic and proteolytic mechanisms. J Biol Chem
1992, 267:26031-26037.
28. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsoh H, Vandlen R, et al: The
carboxyl-terminal domain (111-165) of VEGF is critical for ist mitogenic
potency. J Biol Chem 1996, 271:7788-7795.
29. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML: Processing of
VEGF-A by MMPs regulates bioavailability and vascular patterning in
tumors. J Cell Biol 2005, 169:681-691.
30. van der Veekan J, Oliveira S, Schiffelers RM, Storm G, van Bergen EN,
Henegouwen PM, Roovers RC: Crosstalk between epidermal growth
factor receptor and insulin-like growth factor-1 receptor signaling:
implications for cancer therapy. Curr Cancer Drug Targets 2009, 9:748-760.
31. Cao R, Xue Y, Hedlund EM, Zhong Z, Tritsaris K, Tondelli B, Lucchini F,
Zhu Z, Dissing S, Cao Y: VEGFR1-mediated pericyte ablation links VEGF
and PIGF to cancer-associated retinopathy. Proc Natl Acad Sci USA 2010,
107:856-861.
32. Neagoe PE, Lemieux C, Sirois MG: Vascular endothelial growth factor
(VEGF)-A 165-induced prostacyclin synthesis requires the activation of
VEGF receptor-1 and -2 heterodimer. J Biol Chem 2005, 280:9904-9912.
doi:10.1186/1752-0509-5-170
Cite this article as: Forsten-Williams et al.: Complex receptor-ligand
dynamics control the response of the VEGF system to protease injury.
BMC Systems Biology 2011 5:170.
Forsten-Williams et al. BMC Systems Biology 2011, 5:170
http://www.biomedcentral.com/1752-0509/5/170
Page 15 of 15